These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 31679947)
21. Biomarkers: Their Role in CFTR Modulator Therapies from Early Development to the Clinic. Bell SC; Wood ME Am J Respir Crit Care Med; 2018 Jun; 197(11):1375-1376. PubMed ID: 29406823 [No Abstract] [Full Text] [Related]
22. Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis. Med Lett Drugs Ther; 2018 Oct; 60(1558):174-176. PubMed ID: 30335045 [No Abstract] [Full Text] [Related]
23. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry. Elborn JS; Ramsey B; Wainwright C; Boyle M Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855 [No Abstract] [Full Text] [Related]
24. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related]
25. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE; Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017 [TBL] [Abstract][Full Text] [Related]
27. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037 [TBL] [Abstract][Full Text] [Related]
28. Tezacaftor for the treatment of cystic fibrosis. Sala MA; Jain M Expert Rev Respir Med; 2018 Sep; 12(9):725-732. PubMed ID: 30073878 [TBL] [Abstract][Full Text] [Related]
29. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
30. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
31. [Cystic fibrosis prognosis in Europa : chronicle of an announced dilemma]. Lebecque P; Thimmesch M Rev Med Liege; 2021 Mar; 76(3):202-207. PubMed ID: 33682390 [TBL] [Abstract][Full Text] [Related]
39. A new chapter in therapy for cystic fibrosis. Bilton D Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158 [No Abstract] [Full Text] [Related]
40. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]